Movano Health Commences Clinical Study with New Cuffless Blood Pressure Device
MWN-AI** Summary
Movano Health (Nasdaq: MOVE) has initiated a clinical trial for its new cuffless blood pressure monitoring device, marking a significant advancement in wearable health technology. Beginning February 2025, this trial will involve at least 70 participants who will use the updated wrist wearable to monitor their pulse pressure waveforms, comparing these readings against a standard hospital-grade blood pressure monitor. The device not only measures blood pressure but also collects additional vital signs, including heart rate, blood oxygen saturation (SpO2), respiration rate, and ECG data.
Michael Leabman, Movano’s CTO and Founder, emphasized the improvements made since previous clinical trials, which were conducted in late 2024 and 2023. These enhancements aim to provide higher fidelity data, offering a more reliable non-invasive monitoring solution. The cuffless design represents a crucial step forward in affordable and convenient health monitoring, aligning with the growing trend towards wearable technology in healthcare.
The current study follows three earlier trials that involved over 60 participants of diverse backgrounds, reinforcing Movano's commitment to inclusivity in its research. The company plans to conduct another extensive continuous-blood pressure study in mid-2025, involving 100-150 participants, utilizing arterial monitoring to refine the algorithm for future FDA trials.
Founded in 2018, Movano Health has been dedicated to creating purpose-driven health solutions, seeking to deliver comprehensive, trustworthy health data through innovative designs. Their flagship product, the Evie Ring, exemplifies their goal of utilizing advanced technology to empower proactive health management. As Movano Health advances its clinical studies, it aims to transform the wearable market and improve health outcomes for various patient populations. For further details, visit Movano Health’s website.
MWN-AI** Analysis
Movano Health (Nasdaq: MOVE) has recently initiated a clinical study of its innovative cuffless blood pressure monitoring device, which could significantly impact both its market positioning and driving factors in the wearable health technology sector. This announcement, along with the company's commitment to refining its proprietary technology, suggests a strong potential for growth and investment consideration.
The cuffless blood pressure wearable, designed to monitor vital signs such as pulse rate, blood oxygen saturation, and ECG waveforms, is evolving in sophistication. The completion of the trial in February 2025 and the planned expansion into a larger study later this year underscore a robust strategy aimed at solidifying FDA approvals and gaining traction in the market. Given Movano's track record with previous trials, investor optimism is warranted, especially with expectations around more reliable data collection methods enhancing its value proposition.
Moreover, the wearable health technology market is expected to experience substantial growth, driven by increasing consumer interest in health monitoring solutions. Movano’s target demographic—individuals looking for real-time health insights—is growing, aligning with broader trends in personalized healthcare. The company's ability to leverage clinical data into a competitive edge through future sales of the device will be integral to its financial performance.
Investors should closely monitor the outcomes of the forthcoming clinical studies and regulatory approvals, as successful results could catalyze further market penetration and boost stock valuations. Additionally, consideration of potential partnerships or collaborations could enhance Movano's distribution capabilities and market reach. Holding onto shares may be wise as the company continues to innovate, but caution is advised given the inherent risks of clinical trials and market volatility in the tech health sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
New proprietary RF hardware delivers significantly enhanced signal fidelity
PLEASANTON, Calif. , Feb. 4, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) announced today that it has commenced a blood pressure clinical trial with its newly developed cuffless blood pressure wrist wearable. The study, which is expected to include at least 70 participants and be completed during the second week of February, utilizes the updated device to monitor pulse pressure waveforms in comparison with a hospital grade blood pressure device. The new wearable will also collect data on a host of other vital signs including pulse rate, blood oxygen saturation (SpO 2 ), respiration rate and ECG waveforms.
"We have learned a great deal since our last clinical trial in November 2024 and have refined the use of our proprietary cuffless blood pressure wearable in order to extract higher fidelity data," said Movano Health's CTO and Founder Michael Leabman. "I'm excited about the potential the enhanced design offers relative to our previous prototype as it represents a significant leap forward in cuffless blood pressure monitoring."
The February 2025 study follows three clinical trials that took place in November 2024, June 2024 and October 2023 where the Company used its non-invasive devices to collect pulse pressure waveform data from over 60 participants of varying gender, age, ethnicity and BMI. During each session, participants wore Movano Health's wrist-worn device along with a hospital-grade FDA-cleared vital signs monitor with cuffed blood pressure measurements or utilizing arterial blood pressure data as the control. In mid-2025, the Company plans on executing an additional 100-150 person continuous-blood pressure study using an arterial line, the results of which would help finalize the algorithm expected to be used in a future FDA pivotal trial.
About Movano Health
Founded in 2018, Movano Inc. (Nasdaq: MOVE) dba Movano Health, maker of the Evie Ring ( www.eviering.com ), is developing a suite of purpose-driven healthcare solutions to bring medical-grade data to the forefront of wearables. Featuring modern and flexible form factors, Movano Health's devices offer an innovative approach to delivering trusted data to both customers and enterprises, capturing a comprehensive picture of an individual's health data and uniquely translating it into personalized and intelligent insights.
Movano Health is developing its proprietary technologies and wearable medical device solutions to enable the future use of data as a tool to proactively monitor and manage health outcomes across a number of patient populations that exist in healthcare. For more information on Movano Health, visit https://movanohealth.com/ .
Forward Looking Statements
This press release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding plans with respect to the commercial launches of the Evie Ring and EvieMED Ring; our expectations regarding potential commercial opportunities; planned cost-cutting initiatives; anticipated FDA clearance decisions with respect to our products; expected future operating results; product development and features, product releases, clinical trials and regulatory initiatives; our strategies, positioning and expectations for future events or performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption "Risk Factors." Any forward-looking statement in this release speaks only as of the date of this release. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
SOURCE Movano
FAQ**
How does Movano Inc. MOVE plan to differentiate its cuffless blood pressure device from existing competitors in the market during their upcoming clinical trial?
What specific advancements in signal fidelity have been achieved with Movano Inc. MOVE's new proprietary RF hardware for the cuffless blood pressure wearable?
How will Movano Inc. MOVE ensure the reliability and validity of the data collected in the clinical study compared to traditional blood pressure measurement methods?
What are the anticipated next steps for Movano Inc. MOVE after the completion of this clinical trial, and how might these influence regulatory approvals for their devices?
**MWN-AI FAQ is based on asking OpenAI questions about Movano Inc. (NASDAQ: MOVE).
NASDAQ: MOVE
MOVE Trading
-2.02% G/L:
$13.2619 Last:
9,451 Volume:
$13.32 Open:
